In mid-September, we suggested that investors take a closer look at Pfizer, the big ($211 billion market cap) pharmaceutical company. This article is for paid members - please login or subscribe for access. Username Password Remember Me Forgot Password Share: Mark W. Guthner, CFA Previous Post AMAT: Applied MaterialsNext PostThe bullish case for gold, silver and bitcoin in the long run You Might Also Like Return To South Africa July 10, 2019 USO: Swimming (or Drowning Perhaps) in Oil March 30, 2020 SYF: Synchrony Financial: Out of Sync or Just Misunderstood October 21, 2020
You Might Also Like Return To South Africa July 10, 2019 USO: Swimming (or Drowning Perhaps) in Oil March 30, 2020 SYF: Synchrony Financial: Out of Sync or Just Misunderstood October 21, 2020
